Associations - FGFR3 mutation

FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	infigratinib Sensitive: C2 – Inclusion Criteria J Urol - 3 weeks (NewC2)	infigratinib Sensitive: C2 – Inclusion Criteria J Urol - 3 weeks - (New C3)
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	erdafitinib Sensitive: A1 - Approval	erdafitinib Sensitive: A1 - Approval
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials	BAY 1163877 Sensitive: B - Late Trials
FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	FGFR3 mutation FGFR3 mutation	Cholangiocarcinoma Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label	erdafitinib Sensitive: C1 - Off-label
FGFR3 mutation FGFR3 mutation	Gastric Cancer Gastric Cancer	FGFR3 mutation FGFR3 mutation	Gastric Cancer Gastric Cancer	erdafitinib Sensitive: C1 - Off-label	erdafitinib Sensitive: C1 - Off-label
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria	pemigatinib Sensitive: C2 – Inclusion Criteria
FGFR3 mutation FGFR3 mutation	Bladder Cancer Bladder Cancer	FGFR3 mutation FGFR3 mutation	Bladder Cancer Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria	infigratinib Sensitive: C2 – Inclusion Criteria
FGFR3 mutation FGFR3 mutation	Breast Cancer Breast Cancer	FGFR3 mutation FGFR3 mutation	Breast Cancer Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria	infigratinib Sensitive: C2 – Inclusion Criteria
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria	TAS 120 Sensitive: C2 – Inclusion Criteria
FGFR3 mutation FGFR3 mutation	Non Small Cell Lung Cancer NSCLC	FGFR3 mutation FGFR3 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
FGFR3 mutation FGFR3 mutation	Non Small Cell Lung Cancer NSCLC	FGFR3 mutation FGFR3 mutation	Non Small Cell Lung Cancer NSCLC	nintedanib Sensitive: C3 – Early Trials	nintedanib Sensitive: C3 – Early Trials
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	B-701 Sensitive: C3 – Early Trials	B-701 Sensitive: C3 – Early Trials
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	enfortumab vedotin Resistant: C3 – Early Trials	enfortumab vedotin Resistant: C3 – Early Trials
FGFR3 mutation FGFR3 mutation	Solid Tumor Solid Tumor	FGFR3 mutation FGFR3 mutation	Solid Tumor Solid Tumor	CPL304110 Sensitive: D – Preclinical	CPL304110 Sensitive: D – Preclinical
FGFR3 mutation FGFR3 mutation	Endometrial Cancer Endometrial Cancer	FGFR3 mutation FGFR3 mutation	Endometrial Cancer Endometrial Cancer	infigratinib Sensitive: D – Preclinical	infigratinib Sensitive: D – Preclinical
FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	FGFR3 mutation FGFR3 mutation	Urothelial Cancer Urothelial Cancer	dasatinib + infigratinib Sensitive: D – Preclinical	dasatinib + infigratinib Sensitive: D – Preclinical